Perceptive Advisors LLC Cyma Bay Therapeutics, Inc. Transaction History

Perceptive Advisors LLC

$4.77 Billion
Q1 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $237,330 - $459,815	-18,791 Reduced 0.46%	4,024,400 $95.1 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $3.37 Million - $5.46 Million	309,936 Added 8.3%	4,043,191 $60.3 Million
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $1.27 Million - $1.86 Million	-170,000 Reduced 4.36%	3,733,255 $40.9 Million
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $18.8 Million - $30.6 Million	3,194,262 Added 450.54%	3,903,255 $34 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $2.28 Million - $4.45 Million	708,993 New	708,993 $4.45 Million

Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $2.02 Million - $9.02 Million	-1,520,355 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$5.12 - $7.21 $12 Million - $16.9 Million	-2,342,466 Reduced 60.64%	1,520,355 $7.78 Million
Q2 2019 Aug 14, 2019	SELL	$6.05 - $13.66 $2.12 Million - $4.78 Million	-350,000 Reduced 8.31%	3,862,821 $27.7 Million
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $14.3 Million - $23.5 Million	1,750,000 Added 71.06%	4,212,821 $55.9 Million
Q4 2018 Feb 14, 2019	SELL	$6.54 - $11.74 $1.83 Million - $3.29 Million	-280,000 Reduced 10.21%	2,462,821 $19.4 Million
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $639,600 - $862,800	-60,000 Reduced 2.14%	2,742,821 $36.8 Million
Q1 2018 May 15, 2018	BUY	$9.0 - $15.16 $1.05 Million - $1.77 Million	116,939 Added 4.35%	2,802,821 $33.7 Million
Q4 2017 Feb 14, 2018	BUY	$7.67 - $9.31 $2.57 Million - $3.12 Million	335,000 Added 14.25%	2,685,882 $24.7 Million
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $14 Million - $19.4 Million	2,350,882	2,350,882 $18.9 Million

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.88M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.

Account